Vigabatrin

Modify Date: 2025-08-23 09:34:22

Vigabatrin Structure
Vigabatrin structure
 Common Name Vigabatrin
CAS Number 60643-86-9 Molecular Weight 129.157
Density 1.1±0.1 g/cm3 Boiling Point 277.7±28.0 °C at 760 mmHg
Molecular Formula C6H11NO2 Melting Point N/A
MSDS N/A Flash Point 121.7±24.0 °C
Symbol GHS02 GHS06 GHS08
GHS02, GHS06, GHS08		 Signal Word Danger

 Use of Vigabatrin


Vigabatrin, also known as gamma-vinyl-GABA, is an antiepileptic drug that inhibits the breakdown of γ-aminobutyric acid (GABA) by acting as a suicide inhibitor of GABA transaminase (GABA-T). It is a structural analog of GABA, but does not bind to GABA receptors. Vigabatrin is an irreversible suicide inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the catabolism of GABA, which increases the level of GABA in the brain. Vigabatrin is a racemic compound, and its [S]-enantiomer is pharmacologically active.

 Names

Name vigabatrin
Synonym More Synonyms

 Chemical & Physical Properties

Density 1.1±0.1 g/cm3
Boiling Point 277.7±28.0 °C at 760 mmHg
Molecular Formula C6H11NO2
Molecular Weight 129.157
Flash Point 121.7±24.0 °C
Exact Mass 129.078979
PSA 63.32000
LogP -0.10
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.483
Storage condition Desiccate at +4°C

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
MP7745000
CHEMICAL NAME :
5-Hexenoic acid, 4-amino-
CAS REGISTRY NUMBER :
60643-86-9
LAST UPDATED :
199801
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C6-H11-N-O2
MOLECULAR WEIGHT :
129.18

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
80 mg/kg/4D-I
TOXIC EFFECTS :
Brain and Coverings - changes in surface EEG Behavioral - somnolence (general depressed activity) Behavioral - muscle contraction or spasticity
REFERENCE :
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 342,185,1993
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
57 mg/kg/2D-I
TOXIC EFFECTS :
Brain and Coverings - changes in surface EEG Behavioral - hallucinations, distorted perceptions Behavioral - toxic psychosis
REFERENCE :
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 342,619,1993
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
3 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 18,225,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 18,225,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>2500 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Skin and Appendages - hair
REFERENCE :
NEPHBW Neuropharmacology. (Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 OBW, UK) V.9- 1970- Volume(issue)/page/year: 21,803,1982 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
109 gm/kg/1Y-C
TOXIC EFFECTS :
Brain and Coverings - other degenerative changes Behavioral - food intake (animal) Related to Chronic Data - death
REFERENCE :
TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 18,225,1990
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9 gm/kg/90D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - retinal changes (pigmentary depositions, retinitis, other) Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 15,143,1987
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
73 gm/kg/1Y-C
TOXIC EFFECTS :
Brain and Coverings - other degenerative changes
REFERENCE :
TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 18,225,1990
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
25200 mg/kg/12W-I
TOXIC EFFECTS :
Brain and Coverings - other degenerative changes Related to Chronic Data - death
REFERENCE :
TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 21,480,1993 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
300 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 53,34A,1996
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
300 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 55,165,1997

 Safety Information

Symbol GHS02 GHS06 GHS08
GHS02, GHS06, GHS08
Signal Word Danger
Hazard Statements H225-H301 + H311 + H331-H370
Precautionary Statements P210-P260-P280-P301 + P310-P311
Hazard Codes Xi
Risk Phrases R36/37/38
Safety Phrases S26-S36
RIDADR MP7745000
WGK Germany 2
RTECS MP7745000
HS Code 2922499990

 Customs

HS Code 2922499990
Summary HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0%

 Articles51

More Articles
A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

JAMA Psychiatry 70(6) , 630-7, (2013)

Cocaine dependence is a significant public health problem, yet no validated pharmacological treatment exists. The potent γ-aminobutyric acid (GABA)ergic medication vigabatrin has previously been shown...

Cerebellar fastigial nuclear GABAergic projections to the hypothalamus modulate immune function.

Brain. Behav. Immun. 27(1) , 80-90, (2013)

Our previous work has shown that the cerebellar fastigial nucleus (FN) is involved in modulation of lymphocyte function. Herein, we investigated effect of FN γ-aminobutyric acid (GABA)-ergic projectio...

Vigabatrin versus carbamazepine monotherapy for epilepsy.

Cochrane Database Syst. Rev. 1 , CD008781, (2012)

The efficacy and safety of vigabatrin (VGB) as an add-on therapy for refractory epilepsy has been well established. However, this needs to be weighed against the risk of the development of visual fiel...

 Synonyms

vigabatrinum
4-Aminohex-5-enoic acid
Sabril
EINECS 200-659-6
4-Amino-5-hexenoic acid
UNII:GR120KRT6K
vigabatrinum [INN_la]
vigabatrine
MFCD00274577
Vigabatrin
vigabatrina
(±)-Vigabatrin
5-Hexenoic acid, 4-amino-
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Vigabatrin suppliers

Vigabatrin price

Related Compounds: More...
Vigabatrin
68506-86-5
(S)-Vigabatrin
74046-07-4
(-)-Vigabatrin
77162-51-7
ent-Vigabatrin
1075727-00-2
Vigabatrin impurity E
1378466-25-1
Vigabatrin (Hydrochloride)
1391054-02-6
Vigabatrin related compound B
1379403-11-8
N-Boc-(S)-Vigabatrin methyl ester
197231-54-2
Vigabatrin specified impurity B [EP]
1379504-35-4
1-Ethynyl-2-methoxy-3-nitrobenzene
1609393-94-3
6-chloro-4-((2-methoxypyridin-3-yl)amino)-N-methylnicotinamide
1646337-31-6
2-Nitro-5-(phenylsulfonyl)pyridine
1609560-88-4
1-[(4-Nitrophenyl)sulfonyl]-3-(trifluoromethoxy)benzene
1609560-87-3
6-(5-(5-Aminopyridin-3-yl)thiophen-2-yl)isoindolin-1-one
1567837-10-8
(4-Methyl-6-morpholin-4-yl-5-amino-pyrimidin-2-yl)-(tetrahydro-pyran-4-ylmethyl)-amine
1242158-48-0
Methyl 2-(pyridin-3-yl)cyclopropanecarboxylate
1934941-23-7
3-(4-Fluoro-3-methoxyphenyl)-2-methylpropanoic acid
1564270-15-0
1-(Methylsulfonyl)-3-((4-nitrophenyl)sulfonyl)benzene
107623-36-9
2-Fluoro-4-[(8-quinolinylsulfonyl)amino]benzoic acid
1384448-29-6
Chemsrc provides Vigabatrin(CAS#:60643-86-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Vigabatrin are included as well.>> amp version: Vigabatrin

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved